RedHill Biopharma (RDHL) director Tsimchi Ofer details initial share and option holdings

Rhea-AI Filing Summary

RedHill Biopharma Ltd. director Tsimchi Ofer filed an initial Form 3 reporting his equity holdings in the company. The filing shows direct ownership of 146,250,000 Ordinary Shares and 3,644 American Depositary Shares (ADSs), which are convertible into Ordinary Shares at the holder’s election with no expiration date.

Ofer also reports 14,625 unvested restricted share units, each linked to one ADS and settled in Ordinary Shares. In addition, he holds stock options over 150,000, 90,000 and 180,000 Ordinary Shares, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring on May 6, 2029, March 25, 2030 and April 28, 2031, respectively.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tsimchi Ofer

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	146,250,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(2)	(2)	Ordinary Shares	36,440,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	150,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	90,000	(4)	D
Stock Option (Right to Buy)	(5)	(5)	Ordinary Shares	180,000	(5)	D

Explanation of Responses:

1. Represents 14,625 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

2. Represents 3,644 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

3. Represents stock option to purchase 150,000 Ordinary Shares (equivalent to 15 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.

4. Represents stock option to purchase 90,000 Ordinary Shares (equivalent to 9 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.

5. Represents stock option to purchase 180,000 Ordinary Shares (equivalent to 18 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.

	/s/ Ofer Tsimchi	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Tsimchi Ofer’s Form 3 for RedHill Biopharma (RDHL) show?

The Form 3 discloses Tsimchi Ofer’s initial ownership in RedHill Biopharma. It lists his direct Ordinary Share holdings, ADSs, unvested restricted share units, and several stock option grants, providing a baseline view of his equity position as a director with no new buy or sell activity.

How many RedHill Biopharma (RDHL) Ordinary Shares does Tsimchi Ofer report holding?

Tsimchi Ofer reports direct ownership of 146,250,000 Ordinary Shares. These shares are tied to unvested restricted share units that are settled in Ordinary Shares, giving investors a sense of his substantial equity exposure to RedHill alongside additional ADS and option positions.

What American Depositary Share (ADS) holdings does Tsimchi Ofer disclose for RDHL?

He reports 3,644 American Depositary Shares in RedHill Biopharma. According to the filing, these ADSs are convertible at any time at the holder’s election and have no expiration date, adding another layer to his overall economic interest in the company’s Ordinary Shares.

What stock options in RedHill Biopharma (RDHL) does Tsimchi Ofer hold?

Ofer holds three stock option grants over 150,000, 90,000 and 180,000 Ordinary Shares. These options are fully vested and exercisable, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring between 2029 and 2031 under the RedHill 2010 Option Plan.

Are there any buy or sell transactions reported in this RDHL Form 3?

No buy or sell transactions are reported in this Form 3. The entries are classified as holdings, meaning the document serves as an initial statement of beneficial ownership, not a record of recent market purchases, sales, or option exercises by Tsimchi Ofer.

What restricted share units (RSUs) in RDHL does Tsimchi Ofer report?

He reports 14,625 unvested restricted share units, each linked to one ADS. These RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares, aligning a portion of his compensation with RedHill Biopharma’s long-term share performance as the awards vest.

When do Tsimchi Ofer’s RDHL stock options expire and at what exercise prices?

The options expire in 2029, 2030 and 2031 with different exercise prices. Specifically, the grants have exercise prices of $5,000, $4,870 and $7,080 per ADS, providing long-dated potential for additional Ordinary Share ownership.